Literature DB >> 16641260

Monomeric APOBEC3G is catalytically active and has antiviral activity.

Sandrine Opi1, Hiroaki Takeuchi, Sandra Kao, Mohammad A Khan, Eri Miyagi, Ritu Goila-Gaur, Yasumasa Iwatani, Judith G Levin, Klaus Strebel.   

Abstract

APOBEC3G (APO3G) is a cytidine deaminase that restricts replication of vif-defective human immunodeficiency virus type 1 (HIV-1). Like other members of the cellular deaminase family, APO3G has the propensity to form homo-multimers. In the current study, we investigated the functional determinants for multimerization of human APO3G and studied the role of APO3G multimerization for catalytic activity, virus encapsidation, and antiviral activity. We found that human APO3G is capable of forming multimeric complexes in transfected HeLa cells. Interestingly, multimerization of APO3G was exquisitely sensitive to RNase treatment, suggesting that interaction of APO3G subunits is facilitated or stabilized by an RNA bridge. Mutation of a conserved cysteine residue (C97) that is part of an N-terminal zinc-finger motif in APO3G abolished multimerization of APO3G; however, the C97 mutation inhibited neither in vitro deaminase activity nor antiviral function of APO3G. These results suggest that monomeric APO3G is both catalytically active and has antiviral activity. Interference studies employing either catalytically inactive or packaging-incompetent APO3G variants suggest that wild-type APO3G is packaged into HIV-1 particles in monomeric form. These results provide novel insights into the catalytic function and antiviral property of APO3G and demonstrate an important role for C97 in the RNA-dependent multimerization of this protein.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641260      PMCID: PMC1472092          DOI: 10.1128/JVI.80.10.4673-4682.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

Review 2.  Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business.

Authors:  Joseph E Wedekind; Geoffrey S C Dance; Mark P Sowden; Harold C Smith
Journal:  Trends Genet       Date:  2003-04       Impact factor: 11.639

3.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

4.  The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.

Authors:  Keisuke Shindo; Akifumi Takaori-Kondo; Masayuki Kobayashi; Aierken Abudu; Keiko Fukunaga; Takashi Uchiyama
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

5.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

6.  AID mutant analyses indicate requirement for class-switch-specific cofactors.

Authors:  Van-Thanh Ta; Hitoshi Nagaoka; Nadia Catalan; Anne Durandy; Alain Fischer; Kohsuke Imai; Shigeaki Nonoyama; Junko Tashiro; Masaya Ikegawa; Satomi Ito; Kazuo Kinoshita; Masamichi Muramatsu; Tasuku Honjo
Journal:  Nat Immunol       Date:  2003-08-10       Impact factor: 25.606

7.  Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.

Authors:  Roberto Mariani; Darlene Chen; Bärbel Schröfelbauer; Francisco Navarro; Renate König; Brooke Bollman; Carsten Münk; Henrietta Nymark-McMahon; Nathaniel R Landau
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

8.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

9.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

10.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

View more
  50 in total

1.  The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.

Authors:  Xiaoxia Wang; Zhujun Ao; Liyu Chen; Gary Kobinger; Jinyu Peng; Xiaojian Yao
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.

Authors:  Xiaojun Wang; Patrick T Dolan; Ying Dang; Yong-Hui Zheng
Journal:  J Biol Chem       Date:  2006-12-01       Impact factor: 5.157

3.  Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G.

Authors:  Kuan-Ming Chen; Natalia Martemyanova; Yongjian Lu; Keisuke Shindo; Hiroshi Matsuo; Reuben S Harris
Journal:  FEBS Lett       Date:  2007-09-07       Impact factor: 4.124

4.  APOBEC3G complexes decrease human immunodeficiency virus type 1 production.

Authors:  Kenneth L Martin; Megan Johnson; Richard T D'Aquila
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

5.  Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.

Authors:  Yasumasa Iwatani; Hiroaki Takeuchi; Klaus Strebel; Judith G Levin
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

6.  Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits.

Authors:  Joseph E Wedekind; Richard Gillilan; Alena Janda; Jolanta Krucinska; Jason D Salter; Ryan P Bennett; Jay Raina; Harold C Smith
Journal:  J Biol Chem       Date:  2006-10-31       Impact factor: 5.157

7.  Functional analysis and structural modeling of human APOBEC3G reveal the role of evolutionarily conserved elements in the inhibition of human immunodeficiency virus type 1 infection and Alu transposition.

Authors:  Yannick Bulliard; Priscilla Turelli; Ute F Röhrig; Vincent Zoete; Bastien Mangeat; Olivier Michielin; Didier Trono
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

8.  Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif.

Authors:  Sandra Kao; Ritu Goila-Gaur; Eri Miyagi; Mohammad A Khan; Sandrine Opi; Hiroaki Takeuchi; Klaus Strebel
Journal:  Virology       Date:  2007-09-06       Impact factor: 3.616

9.  APOBEC3G-independent reduction in virion infectivity during long-term HIV-1 replication in terminally differentiated macrophages.

Authors:  Eri Miyagi; Franziska Schwartzkopff; Ronald Plishka; Alicia Buckler-White; Kathleen A Clouse; Klaus Strebel
Journal:  Virology       Date:  2008-08-03       Impact factor: 3.616

Review 10.  Human cellular restriction factors that target HIV-1 replication.

Authors:  Klaus Strebel; Jeremy Luban; Kuan-Teh Jeang
Journal:  BMC Med       Date:  2009-09-16       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.